Cite
HARVARD Citation
Rimassa, L. et al. (n.d.). P-238Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy. Annals of oncology. p. . [Online].